JCB, Volume 22, Number 3, 2016 Article Vol.22 No. 3 (2016) Business Model Innovation Opportunities for the Biopharmaceutical Industry: A Systematic Review James B. Downs Research on business model innovation for the biopharmaceutical industry continues to be an area of high global interest due to the combination of industry innovation challenges and globa Article Vol.22 No. 3 (2016) Bioinformatics Patents - The Challenges Rujita Ravindra Shenoy This paper examines the problems and complexities created by the patent regime as well as challenges posed by accommodating new technologies like bioinformatics in its traditional patent Article Vol.22 No. 3 (2016) Prospects and Challenges for the Commercialization of Biosimilars: Perspectives from the EU, Japan, and the US Joanna Brougher With many blockbuster biologic drugs coming off patent in the next couple of years, biosimilars are making significant breakthroughs in cost-effective biologic therapies. The global marke From the Boardroom Vol.22 No. 3 (2016) Industry Partnerships, Key Success Factor to Win in the Biosimilars Space Catherine Godrecka-Bareau Over the past few years, biosimilars became the promised land of the pharmaceutical industry. Seven out of the top ten drugs are biologics. And all are about to lose patent protection by 202 From the Boardroom Vol.22 No. 3 (2016) Biotechnology, a strategic planning orphan: towards an effective strategy framework for biotechnology firms Peter L Molloy